NCT06261164

Population Pharmacokinetic Model of Amikacin and Vancomycin in Critically Ill Patients

Development and Use of a Population Pharmacokinetic Model of Amikacin and Vancomycin for the Optimization of Dosing Regimens in Critically Ill Patients on Different Modalities of Extracorporeal Hemoadsorption

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: University Clinical Centre of Republic of Srpska · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The object of the scientific research is the characterization of the pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.

Conditions

• Sepsis

Interventions

Type	Name	Description
DEVICE	Cytosorb® and Oxiris® adsorbents	The pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.

Timeline

• Start date: 2024-01-31
• Primary completion: 2024-12-31
• Completion: 2025-01-31
• First posted: 2024-02-15
• Last updated: 2024-02-15

Locations

1 site across 1 country: Bosnia and Herzegovina